The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | The rationale behind targeting Aurora A Kinase in lung cancer
Jong Woo Lee, MD, PhD, Yale Cancer Center and Yale University School of Medicine, New Haven, CT, provides the rationale behind targeting Aurora A Kinase (ARUKA) in lung cancer. ARUKA has been shown to be highly expressed in lung cancer, the expression of which is associated with poor patient outcomes. Additionally, ARUKA has been implicated in acquired resistance to targeted therapy, including to treatments targeting KRASG12C such as sotorasib. Thus, targeting ARUKA may aid in overcoming resistance to such targeted agents. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
